On 23rd June 2021, we welcomed two more partners from the Translation Manchester Research Network to present at our seminar series. Dr Sam Goldsmith & Dr Asmina Pantazi from the Cell and Gene Therapy Catapult and Dr Martin Main from the Medicines Discovery Catapult introduced their organisations and discussed how they support academics with translational research projects.

Watch the event on our YouTube channel: 

Cell and Gene Therapy Catapult

Many companies in the cell and gene therapy industry start in academia, which is why we are actively seeking to work with researchers in the field. We have formed partnerships with many academic institutions across the UK, giving them access to our state-of-the-art development and viral vector laboratories and to our in-house experts. This has included winning grant funding from different sources. If you feel that a research project you are working on addresses an unmet need in the field of cell and gene therapy, we would be interested to hear from you.

We’ll work with you to accelerate your projects, helping your cell and gene therapies to be safer, more effective, scalable and affordable. We make it our job to stay at the forefront of the latest innovations in cell and gene therapies, so that we are ready to help, whenever you might need us.

Medicines Discovery Catapult

At Medicines Discovery Catapult (MDC), we want to fundamentally reshape the UK’s drug-discovery industry. It’s ambitious, and it’s entirely doable.

We’re achieving our aim through collaboration with UK drug discovery organisations. We give them access to industry-leading expertise, cutting-edge technology and superior-quality data. In doing so, we smooth these organisations’ paths to success, accelerating their progress exponentially. New drugs advance to clinical trials more rapidly. Patients get life-improving medicines earlier than they otherwise would have.

MDC’s enthusiastically holistic approach is what makes us unique within drug discovery. Some of our collaborators may only need our help with one specific aspect of their project. Many, however, will find that we can assist with almost every aspect of it – from sample-sourcing, to biomarker analysis, target engagement to statistical analysis, preclinical imaging to syndicated collaborations.”

Related